---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-106567"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-09-10T13:10:47+00:00"
generated_at: "2026-09-10T13:12:10.072129+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Theravance discloses three shareholder lawsuits over Zymeworks merger, supplements proxy

## Summary
- Three complaints filed in NY and CA courts (Aug 25, Aug 26, Sep 2, 2026) seek to enjoin merger and allege omitted info in proxy.
- Company received 13 demand letters alleging disclosure deficiencies; denies all allegations and says no supplemental disclosure required.
- Supplemental disclosures include Lazard's outreach to 60 potential counterparties, 20 confidentiality agreements, and implied equity value range of $15.25-$16.25 per share.
- Net debt as of June 30, 2026 approx. $(385) million; fully diluted shares ~54.9M.
- Evercore to receive $7M fee upon consummation of merger; shareholder meeting set for Sept 18, 2026.

## SEC filing metadata
- accession: 0001104659-26-106567
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-09-10T13:10:47+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926106567/0001104659-26-106567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926106567/tm2624960d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-106567
- JSON: https://secwatch.observer/filing/0001104659-26-106567.json
- Plain text: https://secwatch.observer/filing/0001104659-26-106567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.